Active Ingredient(s): Daunorubicin Liposomal
FDA Approved: * April 8, 1996
Pharm Company: * GILEAD
Category: Cancer

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer.[2] Specifically it is used for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma.[2] It is used by injection into a vein.[2] A liposomal formulation known as liposomal daunorubicin also exists.[2] Common side effects include hair loss, vomiting, bone marrow suppression... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Daunoxome 2 mg/ml Intravenous Injection, Lipid Complex
NDC: 10885-001
Galen Us Inc